97 related articles for article (PubMed ID: 25497216)
21. CCR2B receptor antagonists: conversion of a weak HTS hit to a potent lead compound.
Forbes IT; Cooper DG; Dodds EK; Hickey DM; Ife RJ; Meeson M; Stockley M; Berkhout TA; Gohil J; Groot PH; Moores K
Bioorg Med Chem Lett; 2000 Aug; 10(16):1803-6. PubMed ID: 10969972
[TBL] [Abstract][Full Text] [Related]
22. Discovery and structure-activity relationships of urea derivatives as potent and novel CCR3 antagonists.
Nitta A; Iura Y; Tomioka H; Sato I; Morihira K; Kubota H; Morokata T; Takeuchi M; Ohta M; Tsukamoto S; Imaoka T; Takahashi T
Bioorg Med Chem Lett; 2012 Aug; 22(15):4951-4. PubMed ID: 22749826
[TBL] [Abstract][Full Text] [Related]
23. Indolebutylamines as selective 5-HT(1A) agonists.
Heinrich T; Böttcher H; Bartoszyk GD; Greiner HE; Seyfried CA; Van Amsterdam C
J Med Chem; 2004 Sep; 47(19):4677-83. PubMed ID: 15341483
[TBL] [Abstract][Full Text] [Related]
24. The synthesis of substituted bipiperidine amide compounds as CCR3 ligands: antagonists versus agonists.
Ting PC; Umland SP; Aslanian R; Cao J; Garlisi CG; Huang Y; Jakway J; Liu Z; Shah H; Tian F; Wan Y; Shih NY
Bioorg Med Chem Lett; 2005 Jun; 15(12):3020-3. PubMed ID: 15908209
[TBL] [Abstract][Full Text] [Related]
25. Conformationally restricted indolopiperidine derivatives as potent CCR2B receptor antagonists.
Witherington J; Bordas V; Cooper DG; Forbes IT; Gribble AD; Ife RJ; Berkhout T; Gohil J; Groot PH
Bioorg Med Chem Lett; 2001 Aug; 11(16):2177-80. PubMed ID: 11514164
[TBL] [Abstract][Full Text] [Related]
26. N-Arylalkylpiperidine urea derivatives as CC chemokine receptor-3 (CCR3) antagonists.
Batt DG; Houghton GC; Roderick J; Santella JB; Wacker DA; Welch PK; Orlovsky YI; Wadman EA; Trzaskos JM; Davies P; Decicco CP; Carter PH
Bioorg Med Chem Lett; 2005 Feb; 15(3):787-91. PubMed ID: 15664858
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and biological characterization of 3-substituted-1H-indoles as ligands of GluN2B-containing N-methyl-D-aspartate receptors.
Gitto R; De Luca L; Ferro S; Buemi MR; Russo E; De Sarro G; Costa L; Ciranna L; Prezzavento O; Arena E; Ronsisvalle S; Bruno G; Chimirri A
J Med Chem; 2011 Dec; 54(24):8702-6. PubMed ID: 22050212
[TBL] [Abstract][Full Text] [Related]
28. Design and synthesis of novel CCR3 antagonists.
Gong L; Hogg JH; Collier J; Wilhelm RS; Soderberg C
Bioorg Med Chem Lett; 2003 Oct; 13(20):3597-600. PubMed ID: 14505678
[TBL] [Abstract][Full Text] [Related]
29. Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels.
Yang ZQ; Barrow JC; Shipe WD; Schlegel KA; Shu Y; Yang FV; Lindsley CW; Rittle KE; Bock MG; Hartman GD; Uebele VN; Nuss CE; Fox SV; Kraus RL; Doran SM; Connolly TM; Tang C; Ballard JE; Kuo Y; Adarayan ED; Prueksaritanont T; Zrada MM; Marino MJ; Graufelds VK; DiLella AG; Reynolds IJ; Vargas HM; Bunting PB; Woltmann RF; Magee MM; Koblan KS; Renger JJ
J Med Chem; 2008 Oct; 51(20):6471-7. PubMed ID: 18817368
[TBL] [Abstract][Full Text] [Related]
30. The synthesis of substituted bipiperidine amide compounds as CCR3 antagonists.
Ting PC; Lee JF; Wu J; Umland SP; Aslanian R; Cao J; Dong Y; Garlisi CG; Gilbert EJ; Huang Y; Jakway J; Kelly J; Liu Z; McCombie S; Shah H; Tian F; Wan Y; Shih NY
Bioorg Med Chem Lett; 2005 Mar; 15(5):1375-8. PubMed ID: 15713390
[TBL] [Abstract][Full Text] [Related]
31. CCR2: characterization of the antagonist binding site from a combined receptor modeling/mutagenesis approach.
Berkhout TA; Blaney FE; Bridges AM; Cooper DG; Forbes IT; Gribble AD; Groot PH; Hardy A; Ife RJ; Kaur R; Moores KE; Shillito H; Willetts J; Witherington J
J Med Chem; 2003 Sep; 46(19):4070-86. PubMed ID: 12954060
[TBL] [Abstract][Full Text] [Related]
32. Selective suppression of Th2-mediated airway eosinophil infiltration by low-molecular weight CCR3 antagonists.
Mori A; Ogawa K; Someya K; Kunori Y; Nagakubo D; Yoshie O; Kitamura F; Hiroi T; Kaminuma O
Int Immunol; 2007 Aug; 19(8):913-21. PubMed ID: 17804691
[TBL] [Abstract][Full Text] [Related]
33. Pyrrolidinyl phenylurea derivatives as novel CCR3 antagonists.
Nitta A; Iura Y; Inoue H; Sato I; Morihira K; Kubota H; Morokata T; Takeuchi M; Ohta M; Tsukamoto S; Imaoka T; Takahashi T
Bioorg Med Chem Lett; 2012 Nov; 22(22):6876-81. PubMed ID: 23046963
[TBL] [Abstract][Full Text] [Related]
34. Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners.
Showalter HD; Sercel AD; Leja BM; Wolfangel CD; Ambroso LA; Elliott WL; Fry DW; Kraker AJ; Howard CT; Lu GH; Moore CW; Nelson JM; Roberts BJ; Vincent PW; Denny WA; Thompson AM
J Med Chem; 1997 Feb; 40(4):413-26. PubMed ID: 9046331
[TBL] [Abstract][Full Text] [Related]
35. 3-(4-Piperidinyl)indoles and 3-(4-piperidinyl)pyrrolo-[2,3-b]pyridines as ligands for the ORL-1 receptor.
Bignan GC; Battista K; Connolly PJ; Orsini MJ; Liu J; Middleton SA; Reitz AB
Bioorg Med Chem Lett; 2006 Jul; 16(13):3524-8. PubMed ID: 16632355
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and structure-activity relationship of 7-azaindole piperidine derivatives as CCR2 antagonists.
Xia M; Hou C; DeMong D; Pollack S; Pan M; Singer M; Matheis M; Murray W; Cavender D; Wachter M
Bioorg Med Chem Lett; 2008 Dec; 18(24):6468-70. PubMed ID: 18990568
[TBL] [Abstract][Full Text] [Related]
37. Evolution of novel tricyclic CRTh2 receptor antagonists from a (E)-2-cyano-3-(1H-indol-3-yl)acrylamide scaffold.
Valdenaire A; Pothier J; Renneberg D; Riederer MA; Peter O; Leroy X; Gnerre C; Fretz H
Bioorg Med Chem Lett; 2013 Feb; 23(4):944-8. PubMed ID: 23324405
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and structure-activity relationship of the isoindolinyl benzisoxazolpiperidines as potent, selective, and orally active human dopamine D4 receptor antagonists.
Hendrix JA; Shimshock SJ; Shutske GM; Tomer JD; Kapples KJ; Palermo MG; Corbett TJ; Vargas HM; Kafka S; Brooks KM; Laws-Ricker L; Lee DK; de Lannoy I; Bordeleau M; Rizkalla G; Owolabi J; Kamboj RK
Chembiochem; 2002 Oct; 3(10):999-1009. PubMed ID: 12362366
[TBL] [Abstract][Full Text] [Related]
39. Structure-activity relationship of 5-chloro-2-methyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole analogues as 5-HT(6) receptor agonists.
Mattsson C; Svensson P; Boettcher H; Sonesson C
Eur J Med Chem; 2013 May; 63():578-88. PubMed ID: 23542166
[TBL] [Abstract][Full Text] [Related]
40. Identification of novel short chain 4-substituted indoles as potent alphavbeta3 antagonist using structure-based drug design.
Raboisson P; Desjarlais RL; Reed R; Lattanze J; Chaikin M; Manthey CL; Tomczuk BE; Marugán JJ
Eur J Med Chem; 2007 Mar; 42(3):334-43. PubMed ID: 17184884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
